MuSK-CAART: A novel precision cellular therapy for muscle-specific tyrosine kinase myasthenia gravis
Precision cellular therapy for MuSK myasthenia gravis
Keywords:autoimmunity, neurology, immunotherapy, CAR T cells, neuromuscular junction
Chimeric autoantibody receptor (CAAR) T cells are a novel genetically-engineered T cell immunotherapy that aims to durably eliminate antigen-specific B cells while sparing healthy B cells, ideally leading to safe and lasting remission of B cell-mediated autoimmune diseases with a one-time infusion. We describe the preclinical development of muscle-specific tyrosine kinase CAAR T cells (MuSK-CAART) for the treatment of MuSK myasthenia gravis, a debilitating autoantibody-mediated disease that causes potentially life-threatening muscle weakness.
How to Cite
Copyright (c) 2023 Aimee Payne, Sangwook Oh
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.